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Case Report
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Nasopharynx has a rich submucosal lymphatic network as a result of which 85–90% of cases present with cervical lymphadenopathy, 50% of which is bilateral. 
Hence, most tumors of nasopharynx spread early to cervical 
nodes with frequent distant metastasis [1]. Most commonly, 
Level II lymph nodes are involved (94%) followed closely 
by the lateral retropharyngeal group of lymph nodes (80%), 
and rarely, submental, occipital, mediastinal, axillary nodal 
involvement may also be seen. These tumors also have a high 
frequency of perineural spread along the cranial nerves. About 
80% of primary tumors of the nasopharynx are carcinomas. 
In the majority of cases, they are undifferentiated and related 
to Epstein–Barr virus (EBV) infection or poorly to well-
differentiated squamous cell carcinomas (SCCs) unrelated 
to EBV infection. Other tumors, such as lymphomas, are not 
suitable for brachytherapy [1].
Most of the nasopharyngeal tumors are inoperable due to their 
anatomic situation at the base of the skull. They are, however, 
sensitive enough for local control to be achieved with exclusive 
external beam radio therapy (EBRT) or chemoradiation so that 
endocavitary brachytherapy is indicated in the treatment of 
relatively few cases, as a boost or for recurrent disease. The 
literature data strongly suggest the existence of a dose-response 
relationship in the nasopharynx. 
Furthermore, since the nasopharynx is deeply situated 
and surrounded by bone, vessels, and nerves, to achieve dose 
escalation while maintaining the therapeutic index, the steep 
falloff of brachytherapy dose is essential to achieve the dosimetric 
advantage for an opportunity to treat within the zone of nearby 
critical normal tissue. Of the different methods of brachytherapy 
application, endocavitary techniques are less challenging than the 
interstitial ones.
Here, we report the case of a 58-year-old lady with a history of 
carcinoma nasopharynx presented with recurrence of symptoms 
in the form of nasal blockade along with a right pre-auricular 
swelling.
CASE REPORT
A 58-year-old lady presented to the department with the 
complaints of occasional nasal congestion and a gradually 
progressive, painless, insidious onset, swelling in front of her right 
ear. There were no symptoms of dyspnea, dysphonia, dysarthria, 
or dysphagia. The patient gave a history of nasopharyngeal 
carcinoma (NPC). She was diagnosed and treated at our hospital in 
2003–2004. After the complete clinical evaluation and metastatic 
workup, she was staged as T2N2M0-Stage III disease and was 
started on concurrent chemoradiation. She received EBRT to the 
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face and neck using 6 MV photons on Linac with conventional 
two-dimensional (2D) planning techniques to a total dose of 
4140c gray (Gy)/23# at 5 fractions per week along with weekly 
cisplatin and paclitaxel, of which she received 4 cycles. However, 
mid-way through treatment, she developed Grade 2 mucositis and 
defaulted further chemoradiation despite counseling. Thereafter, 
the patient was lost to follow-up for 9 years.
The patient presented again in the hospital in August 2012, 
with a recurrence of symptoms. On examination, the patient had 
a fairly good Eastern Co-operative Oncology Group (ECOG) 
performance status of 1 with normal vitals. On local examination, 
there was a non-tender 1 cm×1.5 cm firm to hard, mobile right 
pre-auricular nodal region swelling. There was no trismus, 
ankyloglossia, facial asymmetry, or cranial nerve palsy. There 
was no growth or lesion in the oral cavity, oropharynx, or larynx.
On posterior rhinoscopy, there was a small bulge in the 
nasopharynx on the right side near the fossa of Rosenmuller. 
The rest of the ENT examination was normal. Positron emission 
topography-computed tomography scan revealed the bulge as 
well as pre-auricular lymph node to be fluorodeoxy glucose avid. 
A biopsy from the mass as well as from the pre-auricular node 
confirmed a NPC recurrence.
The patient was now labeled as rT1N1M0 Stage II disease 
and was started on concurrent chemoradiation after obtaining 
written informed consent. Her case was discussed in the Joint 
Tumor Board, and in view of a long disease-free interval (DFI) of 
9 years with good response to incomplete therapy, long time since 
previous irradiation, with a good ECOG performance status as 
well as loco-regional and salvageable recurrence, a decision was 
taken to treat her aggressively with curative intent. Furthermore, 
since she had received radiation below tolerance doses to critical 
organ at risk (OAR), so after equieffective dose 2 (EQD2) 
calculations for normal tissue tolerance, a full dose to the tumor 
could be achievable providing that patient compliance could be 
maintained this time. With this ambition, the patient was counseled 
and encouraged before the start of the treatment to prevent her 
from defaulting again. Initially, the patient was unwilling for any 
retreatment; however, later, she agreed on insistence from her 
husband and son. She received 5940 cGy/33#/52 days EBRT to 
the face and neck using 6 MV photons using conventional 2D 
planning techniques on a Siemens dual energy Linac (Model 
Primus) along with 6 cycles of weekly concurrent chemotherapy 
with 40 mg/m2 iv Cisplatin from end August to early October 
2012, after which she further received a boost of 5 Gy×2# of 
high-dose-rate (HDR) brachytherapy, 1 week apart. She tolerated 
all phases well and was compliant to the treatment.
The mucosa of the nasal cavity and the nasopharynx was first 
sprayed with a decongestant (0.05% oxymetazoline hydrochloride) 
and anesthetized with 5% cocaine hydrochloride applied topically 
with cotton swabs. The soft palate was anesthetized with a 
spray of benzocaine, tetracaine hydrochloride, butamben, and 
benzalkonium chloride (cetacaine). Two 5-French pediatric 
feeding tubes with an outer diameter of 1.65 mm and an inner 
diameter of 1.09 mm, respectively, were then introduced into 
the nasopharynx transnasally and withdrawn through the mouth 
transorally to serve as guide tubes for the Rotterdam nasopharynx 
applicator. The applicator was then guided intraorally over 
the pediatric feeding tubes into the nasopharynx and the nasal 
cavity by pulling the nasal portion of the pediatric feeding tubes. 
Placement of the applicator into the nasopharynx was facilitated 
by gentle pushing of the oral portion of the pediatric feeding 
tubes intraorally with a pair of forceps. After the applicator was 
positioned in the nasopharynx and the nasal cavity, the pediatric 
feeding tubes were withdrawn, and the applicator was secured 
in place with a plastic clamp placed over the external portion 
of the applicator outside the nose (Fig. 1). Dummy iridium-192 
sources in afterloading catheters were then inserted into each of 
the tubes of the applicator. After lead markers were placed on 
the contralateral outer canthus and tragus, a pair of orthogonal 
anterior-posterior and lateral localization X-ray films with the 
dummy sources in place were obtained (Fig. 2). The points of 
interest, including the nasopharynx, base of the skull, node of 
Rouviere, pituitary, optic chiasm, spinal cord, and the palate 
points, were marked on the localization films.
Treatment planning and optimization were then performed with 
a computer software program (Plato brachytherapy afterloading 
planning system). Points were selected which should receive the 
reference dose. Usually, these are the nasopharynx points (Na) 
and the Rouviere node (R) (Fig. 3). The dose distribution was 
optimized such that these points receive the prescribed dose. They 
can be assigned a weighting factor for dose requirements, in case 
of inadequate optimization. After treatment planning, afterloading 
catheters were then inserted into the applicator and connected to 
a remote-controlled, HDR afterloading machine for treatment 
Figure 1: (a-c) Endocavitary brachytherapy applicator insertion 
procedure on the patient
a b c
Figure 2: (a and b) Labelled orthogonal X-rays of the patient
a b
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delivery. After completion of treatments, the nose clamp and the 
afterloading catheters were removed. Two 5-French pediatric 
feeding tubes were reinserted into the applicator and the applicator 
was withdrawn through the mouth by pushing it into the nose 
while gently pulling on the feeding tubes exiting the mouth. The 
patient was re-called after 3 and 6 months for follow-up.
DISCUSSION
The carcinoma of the nasopharynx is relatively common in Asian 
countries as compared to the Western countries [2]. In most cases, 
the initial symptoms are a nasal obstruction and/or hypoacousia, 
while progression can be with cervical nodal involvement or 
cranial nerve paralysis.
We chose our patient’s case for publishing a report due to its 
uniqueness. In most cases, recurrent cases are not eligible for full 
dose re-radiation, as tolerance values of OARs have already been 
reached in the first treatment. However, the peculiarity of our case 
was such that since the patient had defaulted mid-way through 
treatment, her total EQD2 was way below tolerance levels, giving 
us a window of opportunity to treat her aggressively to the full 
dose. Furthermore, this case is a rare example of the achievement 
of good locoregional control as reflected by a DFI of 9 years, 
highlighting probably the underlying favorable tumor biology in 
the first instance. The literature supports an aggressive approach to 
management of locoregional nasopharyngeal recurrences as these 
are largely salvageable. Our patient too has been in remission 
with very few side effects (occasional rhinorrhea manageable 
with conservative treatment), for the past 6 years, supporting this 
logic further.
The Rotterdam nasopharyngeal applicator [2,3] is an 
inexpensive, reusable, and flexible silicone applicator, tailored to 
the shape of the soft tissues of the nasopharynx and generally well 
tolerated by patients. It is suitable for applications with stepping 
source after loaders for post-delivery room or HDR-brachytherapy, 
as well as for classical low-dose rate. Depending on the epicenter 
of the tumor, for instance, in case of low to mid-posterior wall, a 
transoral or transnasal approach and, for a high posterior wall, a 
transpalatal approach or split-palate approach can be used. It can 
remain in situ for the duration of the treatment, which varies from 
2 to 6 days, and can be performed on an outpatient department 
basis in case of HDR brachytherapy. The shape of the silicone 
applicator closely conforms to the nasopharyngeal vault. The 
two silicone tubes, with an outer diameter of 15 French and an 
inner diameter of 9 French, can accommodate standard 6 French 
afterloading catheters. The radioactive sources are consequently 
positioned closer to the base of the skull than to the soft palate.
Even though three-dimensional (3D) cardiac resynchronization 
therapy (CRT), intensity-modulated radiation therapy, and 
stereotactic radiotherapy are the mainstays of treatment of NPC 
with very encouraging outcomes, many radiotherapy centers still 
rely on a 2D technique to treat the numerous patients referred 
to them. Until these centers adopt 3D-CRT as a standard, they 
will need to optimize the resources available. Dose escalation 
directly correlates with better locoregional control and prolonged 
overall survival in NPC. The inherent physical and dosimetric 
characteristics of brachytherapy allow the delivery of a high 
dose to the nasopharynx at the same time minimizing the dose to 
adjacent structures.
As per the literature, brachytherapy, although associated with 
major complications, provides reasonable long-term outcomes 
in salvaging recurrent NPC. In one of the earliest retrospective 
comparative studies [4], there was a benefit in local relapse-free 
survival (LRFS) as well as overall survival for patients treated 
for T1-4 carcinoma of the nasopharynx treated by EBRT plus 
endocavitary brachytherapy boost (between 1997 and 1994), as 
opposed to patients treated by EBRT only (between 1978 and 
1988) to a minimum dose of 60 Gy (Fig. 4a). However, there was 
a significant excess death rate due to intercurrent disease and/or 
second primaries. The gain in local control was mainly confined 
to the T1-3 patient category. Except for a few patients developing 
synechiae, no significant difference in morbidity was observed 
Figure 3: Dosimetry points
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for patients treated by external radiotherapy only compared with 
those treated by external radiotherapy plus brachytherapy. In this 
study, however, only primary disease and only SCC histology 
were included, and recurrent disease was excluded.
The N stage at recurrence is a significant prognostic factor 
for both LRFS and disease free survival. Several publications [5] 
(Fig. 4b) have reported that re-irradiation dose is one of the 
most important factors for local-regional progression after the 
salvage treatment. The general consensus is that re-irradiation 
dose above 60 Gy is needed for effective salvage [6,7]. For 
small-volume recurrences treated with brachytherapy alone, 
Choy et al. [8] reported a local control rate of 61% at 5 years 
with 60 Gy delivered by gold grain implants. Moreover, the local 
control was superior in failures confined to the nasopharynx 
compared to failures extending beyond the nasopharynx, 81 
versus 44%, respectively. Similar results have been observed 
by Kwong et al. [9] who observed an overall survival rate at 
5 years of 54%, with the sequelae of headache, palatal fistula, 
and mucosal radiation necrosis at the site of implantation in 
28, 19, and 16% of the patients, respectively. On the other 
hand, Zheng et al. [10] reported that the 5-year actuarial local 
failure-free survival rate of patients with initially diagnosed 
T3–T4 disease for the 3D conformal radiotherapy group and 
brachytherapy group was 84 versus 60%, with 3D conformal 
radiotherapy providing better local control than brachytherapy 
as a salvage treatment for locally persistent NPC, especially in 
patients with initially diagnosed T3–T4 disease.
Results from a contemporary literature are available from a 
study carried out between July 1996 and March 2008, whereby 
29 patients were re-irradiated for locally recurrent nasopharyngeal 
cancer (LR-NPC) treated at Memorial Sloan Kettering Cancer 
Center, New York. 13 patients received combined-modality 
treatment (CMT), consisting of EBRT followed by intracavitary 
brachytherapy, whereas 16 received EBRT alone. The median 
follow-up for all patients was 45 months and for surviving 
patients was 54 months. A 5-year actuarial local control, event-
free survival, and overall survival rates were 52%, 44%, and 60%, 
respectively. No difference was observed between patients treated 
with EBRT and CMT. Overall survival was superior in patients 
who achieved local control (p=0.0003) [11]. The incidence of 
late Grade ≥3 events in patients retreated with EBRT alone was 
significantly increased compared with those receiving CMT 
(73% vs. 8%; p=0.005). In this modern re-irradiation series of 
patients with LR-NPC, favorable overall survival was achieved 
in comparison to historical series. Patients treated with CMT 
experienced significantly fewer severe late effects compared with 
those treated with EBRT. The authors strongly recommended the 
addition of brachytherapy to early-stage recurrences.
CONCLUSION
Intracavitary brachytherapy using the Rotterdam’s nasopharyngeal 
applicator is an easy to use, patient-friendly, economical alternative 
for dose escalation in recurrent NPC at institutes where conformal 
and complex radiation treatment techniques are not yet available. 
It provides a reasonable hope for long-term locoregional control 
as well as increased overall survival in selected patients of 
recurrent NPC with acceptable morbidity.
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